Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer

Table 3 Comparison of prognostic factors according to the numbers of peptide-specific responses (n = 36 HLA-A*2402-matched patients)

Variables	The number of peptide specific response		p-value
Variables	0 or 1	2 or 3	p-value
the number of patients	10	26
Age	69.3 ± 3.7	60.5 ± 2.4	0.1075
Gender			0.4629
Male	6	11
Female	4	15
Stage (UICC)			0.5209
III	2	5
IV	8	18
Recurrence	0	3
NLR	3.61 ± 0.32	2.14 ± 0.16	0.0007
CRP	1.39 ± 0.48	0.58 ± 0.17	0.1425
IL-6	2.11 ± 0.70	19.40 ± 17.32	0.7640
PD-1+ CD4+ T cell	3.46 ± 0.56	1.58 ± 0.17	0.0007
Tim-3+ CD4+ T cell	3.30 ± 0.53	3.71 ± 0.68	0.8184
PD-1+ CD8+ T cell	5.63 ± 0.74	4.05 ± 0.45	0.0689
Tim-3+ CD8+ T cell	5.37 ± 0.98	4.77 ± 0.49	0.7108
Treg	2.41 ± 0.28	1.64 ± 0.13	0.0121
MDSC	17.34 ± 1.70	14.29 ± 0.78	0.1005

Statistical significant results are highlighted in bold letters
Abbreviations: HLA human leukocyte antigen, CI confidence interval, UICC Union for International Cancer, NLR neutrophil lymphocyte ration, CRP C-reactive protein, IL-6 interleukin-6, PD-1 Programmed death-1, Tim-3 T cell immunoglobulin mucin-3, Treg Regulatory T cell, MDSC Myeloid-derived suppressor cell

ISSN: 1756-9966